The company manufactures and distributes drip irrigation systems and related plastic products, primarily serving the agricultural sector in India.
The company lacks a sustainable competitive advantage, as evidenced by its closed production unit for over three years and reliance on trading activities. Financial performance is highly volatile with low average returns on capital, suggesting no pricing power or scale benefits.
Management has struggled to deploy capital effectively, with the manufacturing unit remaining idle for years. Recent actions involve increasing authorized share capital and issuing bonus shares despite a lack of core business growth.
The company's transition from a manufacturer to a mere trading house finalized its decline as the idle production unit eventually became a stranded asset. The capital misallocated to defunct entities was never recovered, and the lack of a permanent auditor signaled deeper internal rot that eventually led to a total loss of investor confidence. Without a core operational engine, the business devolved into a shell company, with the bonus shares serving only to dilute what little value remained before the stock price collapsed to reflect its negligible intrinsic worth.
RichFakir rates Narmada Macplast Drip Irrigation Systems Ltd's business quality as mediocre — 46/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Narmada Macplast Drip Irrigation Systems Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Narmada Macplast Drip Irrigation Systems Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Narmada Macplast Drip Irrigation Systems Ltd's fair value is about ₹3 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →